Nothing Special   »   [go: up one dir, main page]

NO20062832L - Nye salicylanilider - Google Patents

Nye salicylanilider

Info

Publication number
NO20062832L
NO20062832L NO20062832A NO20062832A NO20062832L NO 20062832 L NO20062832 L NO 20062832L NO 20062832 A NO20062832 A NO 20062832A NO 20062832 A NO20062832 A NO 20062832A NO 20062832 L NO20062832 L NO 20062832L
Authority
NO
Norway
Prior art keywords
new
anilides
new salicylic
salicylic anilides
salicylanilides
Prior art date
Application number
NO20062832A
Other languages
English (en)
Inventor
Holger Claus Hansen
Preben Houlberg Olesen
Thomas Kruse Hansen
Lise Brown Christiansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20062832L publication Critical patent/NO20062832L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Color Printing (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Nye salicylanilider er kjemiske avkoblere som for eksempel kan brukes for behandlingen av overvekt.
NO20062832A 2003-11-25 2006-06-16 Nye salicylanilider NO20062832L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301738 2003-11-25
US52637803P 2003-12-01 2003-12-01
PCT/DK2004/000304 WO2005051894A1 (en) 2003-11-25 2004-05-04 Novel salicylic anilides

Publications (1)

Publication Number Publication Date
NO20062832L true NO20062832L (no) 2006-06-16

Family

ID=34635235

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062832A NO20062832L (no) 2003-11-25 2006-06-16 Nye salicylanilider

Country Status (11)

Country Link
US (2) US7645791B2 (no)
EP (1) EP1689700A1 (no)
JP (1) JP2007513880A (no)
KR (1) KR20060101500A (no)
AU (1) AU2004293133A1 (no)
BR (1) BRPI0416933A (no)
CA (1) CA2545023A1 (no)
IL (1) IL175154A0 (no)
NO (1) NO20062832L (no)
RU (1) RU2006116421A (no)
WO (1) WO2005051894A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756025A1 (en) * 2004-05-05 2007-02-28 Novo Nordisk A/S Sulfonamide derivatives
WO2006125778A1 (en) * 2005-05-23 2006-11-30 Novo Nordisk A/S Novel trifluoromethoxy-substituted aryl anilides
WO2006125781A2 (en) * 2005-05-23 2006-11-30 Novo Nordisk A/S Haloalkoxy-substituted salicylic anilides
CA2659655A1 (en) * 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
EP2097380A1 (en) * 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
EP2097391A1 (en) * 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes
EP2086951B1 (en) * 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
CA2669884A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
CN103097385B (zh) 2010-07-14 2016-08-03 诺华股份有限公司 Ip受体激动剂杂环化合物
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
EP2956455B1 (en) 2013-02-13 2017-05-17 Novartis AG Ip receptor agonist heterocyclic compounds
EP3565806B1 (en) 2017-01-06 2022-03-02 Rivus Pharmaceuticals, Inc. Novel phenyl derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34102C (de) TH. GARE in Stockpprt Cheshire, England Neuerungen an Maschinen zum Zurechtschneiden, Poliren, Ausfertigen und Putzen von Stiefeln oder Schuhen
CH281901A (de) * 1950-04-25 1952-03-31 Hoffmann La Roche Verfahren zur Herstellung eines neuen Tropasäureabkömmlings.
GB728098A (en) * 1952-03-05 1955-04-13 Geigy Ag J R Improvements relating to salicylanilides and their use
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
GB1493375A (en) * 1974-09-20 1977-11-30 Ici Ltd Salicylanilide derivatives
US4673691A (en) * 1984-11-05 1987-06-16 Nicholas Bachynsky Human weight loss inducing method
JP2668231B2 (ja) 1987-12-29 1997-10-27 大日精化工業株式会社 電子写真感光体
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
CA2337690C (en) 1998-07-27 2013-10-01 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
JP3937200B2 (ja) * 1998-09-10 2007-06-27 三井化学株式会社 新規な遷移金属錯体、オレフィン重合用触媒およびオレフィンの重合方法
AU6228000A (en) * 1999-07-23 2001-02-13 Allergan Sales, Inc. The use of retinoid receptor antagonists in the treatment of prostate carcinoma
US20030232789A1 (en) 1999-12-15 2003-12-18 Allen Darin Arthur Salicylamides as serine protease and factor xa inhibitors
AU2001259354A1 (en) 2000-05-02 2001-11-12 Smith Kline Beecham Corporation Phosphate transport inhibitors
US6790569B2 (en) 2000-06-13 2004-09-14 Eastman Kodak Company Color photothermographic elements comprising phenolic thermal solvents
TWI280876B (en) * 2002-06-05 2007-05-11 Inst Med Molecular Design Inc Therapeutic drug for diabetes
AU2003242108B2 (en) * 2002-06-10 2008-09-11 Institute Of Medicinal Molecular Design, Inc. Medicament for treatment of cancer
AU2003275939A1 (en) * 2002-11-08 2004-06-07 Novo Nordisk A/S Safe chemical uncouplers for the treatment of obesity

Also Published As

Publication number Publication date
EP1689700A1 (en) 2006-08-16
JP2007513880A (ja) 2007-05-31
US20090005434A1 (en) 2009-01-01
KR20060101500A (ko) 2006-09-25
US20100075932A1 (en) 2010-03-25
US7645791B2 (en) 2010-01-12
RU2006116421A (ru) 2008-01-10
IL175154A0 (en) 2006-09-05
WO2005051894A1 (en) 2005-06-09
AU2004293133A1 (en) 2005-06-09
BRPI0416933A (pt) 2007-01-16
CA2545023A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
NO20062832L (no) Nye salicylanilider
MX2019008592A (es) Compuestos químicos como inhibidores de la actividad de la interleuquina-1.
NO20081042L (no) PPAR aktive forbindelser
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
NO20081636L (no) FAP - inhibitorer
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
DK1594858T3 (da) Nye benzoimidazol-derivater, der kan anvendes som antiproliferative midler
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
IS6251A (is) Not af mónóamín oxíðasa lötum fyrir framleiðslu ályfjum ætluðum til meðhöndlunar á offitu
CY1105085T1 (el) Ενωσεις τυπου ν-φορμυλο υδροξυλαμινης ως αναστολεις της pdf
TW200519089A (en) Biaryl sulfonamides and methods for using same
SE0203752D0 (sv) New compounds
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
ATE541848T1 (de) Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
TR200102969T2 (tr) Siklik protein tirozin kinaz önleyicileri.
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
NO20071534L (no) Behandling av inflammatoriske forstyrrelser og smerte
NO20065907L (no) Nye tetrahydropyridotiofener
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application